Skip to content

Local infiltration analgesia with or without adrenaline in TKA

Adrenaline use in local infiltration analgesia during TKA: randomized, double blind, controlled pilot study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON25265
Enrollment
20
Registered
2014-09-04
Start date
2014-05-09
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients who will undergo TKA placement are potential subjects for this pilot study

Interventions

Post operative LIA after TKA either with ropivacaine or the standard LIA procedure with ropivacaine and adrenaline mixture.

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: •Painful and disabled knee joint resulting from osteoarthritis •High need to obtain pain relief and improve function •Able and willing to follow instructions •Consent form read, understood and signed by patient.

Exclusion criteria

Exclusion criteria: •Active infection in knee •General infection •Distant foci of infections which may spread to the implant site •Failure of previous joint replacement •Pregnancy •Contraindication for ropivacaine •Contraindication for adrenaline

Design outcomes

Primary

MeasureTime frame
•VAS pain score direct post operative and 16:00H and 22:00H on the operative day. •VAS pain score before and after the first mobilisation. •VAS pain score at 8:00H, 16:00H and 22:00H till day of discharge

Secondary

MeasureTime frame
• Amount of post operative analgesia use direct post operative till day of discharge • Time to first mobilisation • Length of hospital stay • Adverse events/complications: Intra-operative, post-operative during pilot study

Contacts

Public ContactM.G.M. Schotanus

Department of Orthopedic Surgery, Orbis Medisch Centrum dr H vd Hoffplein 1

m.schotanus@zuyderland.nl+31 (0)88 4597823

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)